Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 02-Jul-24 6:07 PM View:  | Adler Reid G. CHF CORP DEVEL OFF, GEN COUNS | Vistagen Therapeutics, Inc. (VTGN) | 28-Jun-24 | Grant | 4,854 | $2.96 | $14,358.10 | 42% 11.65K to 16.51K | |
| 02-Jul-24 6:06 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 28-Jun-24 | Grant | 4,854 | $2.96 | $14,358.10 | 18% 26.51K to 31.36K | |
| 02-Jul-24 6:10 PM View: | Prince Joshua S. Chief Operating Officer | Vistagen Therapeutics, Inc. (VTGN) | 28-Jun-24 | Grant | 2,671 | $2.96 | $7,900.82 | 100% 0 to 2.67K | |
| 02-Jul-24 6:08 PM View: | Anderson Cynthia Lynn CHIEF FINANCIAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 28-Jun-24 | Grant | 3,592 | $2.96 | $10,625.10 | 100% 0 to 3.59K | |
| 03-Jan-24 5:19 PM View: | Adler Reid G. CHF CORP DEVEL OFF, GEN COUNS | Vistagen Therapeutics, Inc. (VTGN) | 29-Dec-23 | Grant | 167 | $1.72 | $286.74 | 1% 11.49K to 11.65K | 4% |
| 03-Jan-24 5:17 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 29-Dec-23 | Grant | 167 | $1.72 | $286.74 | < 1% 26.34K to 26.51K | 4% |
| 09-Aug-23 4:10 PM View: | Commodore Capital Lp 10% Owner | Vistagen Therapeutics, Inc. (VTGN) | 07-Aug-23 | Purchase | 775,756 | $23.15 | $17,961,100.00 | 97% 799.24K to 1.57M | |
| 05-Jul-23 4:05 PM View: | Dotson Jerrold Duane VP, CFO | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-23 | Grant | 167 | $1.59 | $265.45 | 5% 3.5K to 3.67K | 13% |
| 05-Jul-23 4:05 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-23 | Grant | 167 | $1.59 | $265.45 | < 1% 26.17K to 26.34K | 13% |
| 05-Jul-23 4:05 PM View: | Adler Reid G. CHIEF LEGAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-23 | Grant | 167 | $1.59 | $265.45 | 1% 11.32K to 11.49K | 13% |
| 03-Jan-23 4:10 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 30-Dec-22 | Grant | 5,000 | $0.09 | $438.00 | < 1% 780.23K to 785.23K | |
| 03-Jan-23 4:11 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 30-Dec-22 | Grant | 5,000 | $0.09 | $438.00 | 5% 100.11K to 105.11K | |
| 22-Aug-22 5:12 PM View: | Gin Jerry B Director | Vistagen Therapeutics, Inc. (VTGN) | 18-Aug-22 | Purchase | 100,000 | $0.18 | $17,870.00 | 33% 300.0K to 400.0K | |
| 22-Aug-22 5:12 PM View: | Gin Jerry B Director | Vistagen Therapeutics, Inc. (VTGN) | 18-Aug-22 | Private Purchase | 100,000 | $0.18 | $17,870.00 | 50% 200.0K to 300.0K | |
| 19-Aug-22 3:45 PM View: | Adler Reid G. CHIEF LEGAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 17-Aug-22 | Private Purchase | 300,000 | $0.17 | $50,910.00 | 866% 34.63K to 334.63K | |
| 18-Aug-22 3:56 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 17-Aug-22 | Private Purchase | 600,000 | $0.17 | $103,200.00 | 333% 180.23K to 780.23K | |
| 15-Jul-22 4:30 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 30-Jul-22 | Grant | 5,000 | $0.75 | $3,740.00 | 5% 95.11K to 100.11K | |
| 14-Jul-22 5:33 PM View: | Venrock Healthcare Capital ... 10% Owner | Vistagen Therapeutics, Inc. (VTGN) | 12-Jul-22 | Sale | 60,000 | $0.89 | $53,400.00 | (< 1%) 20.7M to 20.64M | |
| 15-Jul-22 4:30 PM View: | Smith Mark Alan CHIEF MEDICAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-22 | Grant | 5,000 | $0.75 | $3,740.00 | 34% 14.91K to 19.91K | |
| 15-Jul-22 4:30 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-22 | Grant | 5,000 | $0.75 | $3,740.00 | 3% 175.23K to 180.23K | |
| 16-May-22 1:39 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 12-May-22 | Option Exercise | 100,000 | $1.00 | $100,000.00 | 133% 75.23K to 175.23K | |
| 12-Jan-22 5:21 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 11-Jan-22 | Option Exercise | 18,750 | $1.00 | $18,750.00 | 25% 75.82K to 94.57K | |
| 03-Jan-22 4:25 PM View: | Smith Mark Alan CHIEF MEDICAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-21 | Grant | 2,655 | $1.66 | $4,400.66 | 22% 12.26K to 14.91K | |
| 03-Jan-22 4:17 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-21 | Grant | 3,623 | $1.66 | $6,005.12 | 5% 71.61K to 75.23K | |
| 03-Jan-22 4:20 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-21 | Grant | 3,575 | $1.66 | $5,925.56 | 5% 72.25K to 75.82K | |
| 03-Jan-22 4:19 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-21 | Grant | 3,623 | $1.66 | $6,005.12 | 4% 95.24K to 98.86K | |
| 08-Sep-21 6:58 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 07-Sep-21 | Market Sale | 30,000 | $3.12 | $93,750.00 | (29%) 102.79K to 72.79K | (< 1%) |
| 03-Sep-21 4:19 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 02-Sep-21 | Gift | 1,111 | -- | -- | 1% 94.13K to 95.24K | |
| 03-Sep-21 4:19 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 23-Aug-21 | Gift | 740 | -- | -- | (< 1%) 94.86K to 94.13K | |
| 18-Aug-21 6:20 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 17-Aug-21 | Market Purchase | 3,750 | $2.73 | $10,237.50 | 4% 91.11K to 94.86K | (< 1%) |
| 02-Jul-21 10:00 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-21 | Grant | 3,044 | $1.95 | $5,925.15 | 30% 10.0K to 13.04K | |
| 02-Jul-21 10:00 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-21 | Option Exercise | 89,742 | $0.94 | $84,328.00 | 688% 13.04K to 102.79K | |
| 27-Apr-21 4:13 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 23-Apr-21 | Option Exercise | 5,000 | $1.50 | $7,500.00 | 8% 61.61K to 66.61K | |
| 22-Mar-21 7:06 PM View: | Underdown Brian J. Director | Vistagen Therapeutics, Inc. (VTGN) | 19-Mar-21 | Option Exercise | 2,500 | $1.50 | $3,750.00 | 100% 0 to 2.5K | |
| 22-Mar-21 7:03 PM View: | Saxe Jon S Director | Vistagen Therapeutics, Inc. (VTGN) | 19-Mar-21 | Option Exercise | 2,500 | $1.50 | $3,750.00 | 5% 53.25K to 55.75K | |
| 04-Jan-21 4:58 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-20 | Grant | 5,000 | $0.45 | $2,260.50 | 9% 56.61K to 61.61K | |
| 04-Jan-21 4:57 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-20 | Grant | 5,000 | $0.45 | $2,260.50 | 100% 5.0K to 10.0K | |
| 04-Jan-21 4:48 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-20 | Grant | 5,000 | $0.45 | $2,260.50 | 6% 82.72K to 87.72K | |
| 04-Jan-21 4:55 PM View: | Smith Mark Alan CHIEF MEDICAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 31-Dec-20 | Grant | 5,000 | $0.45 | $2,260.50 | 100% 5.0K to 10.0K | |
| 24-Aug-20 4:31 PM View: | Saxe Jon S Director | Vistagen Therapeutics, Inc. (VTGN) | 21-Aug-20 | Market Purchase | 30,000 | $0.69 | $20,700.00 | 129% 23.25K to 53.25K | |
| 01-Jul-20 5:35 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-20 | Grant | 5,000 | $0.45 | $2,240.00 | 6% 77.72K to 82.72K | |
| 01-Jul-20 5:33 PM View: | Smith Mark Alan CHIEF MEDICAL OFFICER | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-20 | Grant | 5,000 | $0.45 | $2,240.00 | 100% 0 to 5.0K | |
| 01-Jul-20 5:20 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-20 | Grant | 5,000 | $0.45 | $2,240.00 | 10% 51.61K to 56.61K | |
| 01-Jul-20 5:28 PM View: | Dotson Jerrold Duane VP, CFO AND SECRETARY | Vistagen Therapeutics, Inc. (VTGN) | 30-Jun-20 | Grant | 5,000 | $0.45 | $2,240.00 | 100% 0 to 5.0K | |
| 21-Nov-19 7:52 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 20-Nov-19 | Market Purchase | 15,000 | $0.34 | $5,100.00 | 24% 62.72K to 77.72K | 90% |
| 14-Mar-19 5:22 PM View: | Saxe Jon S Director | Vistagen Therapeutics, Inc. (VTGN) | 14-Mar-19 | Market Purchase | 7,920 | $1.27 | $10,086.10 | 52% 15.33K to 23.25K | (45%) |
| 14-Mar-19 5:22 PM View: | Saxe Jon S Director | Vistagen Therapeutics, Inc. (VTGN) | 13-Mar-19 | Market Purchase | 12,080 | $1.26 | $15,201.50 | 372% 3.25K to 15.33K | (44%) |
| 14-Mar-19 5:12 PM View: | Snodgrass H. Ralph PRES./CHIEF SCIENTIFIC OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 13-Mar-19 | Option Exercise | 2,500 | $1.50 | $3,750.00 | 4% 60.22K to 62.72K | |
| 30-Jan-19 4:05 PM View: | Saxe Jon S Director | Vistagen Therapeutics, Inc. (VTGN) | 29-Jan-19 | Option Exercise | 1,375 | $1.50 | $2,062.50 | 73% 1.88K to 3.25K | (53%) |
| 15-Jan-19 4:29 PM View: | Singh Shawn CHIEF EXECUTIVE OFFICER Director | Vistagen Therapeutics, Inc. (VTGN) | 14-Jan-19 | Option Exercise | 25,375 | $1.50 | $38,062.50 | 97% 26.23K to 51.61K |
